Nexalin Technology, Inc.

NXL Nasdaq SEC CIK 1527352
Follow Nexalin Technology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $78.3K +331.4% vs same quarter last year
Net income −$2.7M −16.9% vs same quarter last year
EPS, diluted −$3.43 +10.7% vs same quarter last year
Operating cash flow −$1.6M −8.3% vs same quarter last year
Revenue by quarter
$27.2K
$41K
$70.6K
$18.1K
$171.9K
$15K
$12.2K
$78.3K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$10M−$7.5M−$5M−$2.5M$0$2.5MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$301.6K−$8.2M
FY24$168.7K−$7.6M
FY23$110.7K−$4.6M
FY22$1.3M−$1.7M
FY21$144.1K−$6.1M
FY20--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−6000%−4000%−2000%0%2000%FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2579.7%−2781.7%−2725.8%
FY2478.3%−4596.1%−4508.7%
FY2376.8%−5143.5%−4197.6%
FY2272.5%−138.7%−128.5%
FY2185.1%−4177.7%−4218.9%
FY20---
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Nexalin Technology
  • Healthcare median
−6000%−4000%−2000%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearNexalin TechnologyHealthcare median
FY25−2725.8%−30.6%
FY24−4508.7%−47%
FY23−4197.6%−58%
FY22−128.5%−80.4%
FY21−4218.9%−71.8%
FY20-−62.2%